Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aura Biosciences, Inc. (AURA : NSDQ)

• Company Description    Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company's lead product candidate includes AU-011. Aura Biosciences Inc. is based in CAMBRIDGE, Mass. Number of Employees: 113

• Price / Volume Information    Yesterday's Closing Price: $7.60 Daily Weekly Monthly 20 Day Moving Average: 833,866 shares Shares Outstanding: 103.39 (millions) Market Capitalization: $785.74 (millions) Beta: 0.37 52 Week High: $9.54 52 Week Low: $4.73 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.68% -0.43% 12 Week 27.09% 17.49% Year To Date 39.45% 29.05%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 80 GUEST STREET - BOSTON,MA 02135 USA ph: 617-500-8864 fax: - ir@aurabiosciences.com http://www.aurabiosciences.com

• General Corporate Information    Officers Elisabet de los Pinos - President and Chief Executive Officer David Johnson - Chairman of the Board of Directors Amy Elazzouzi - Senior Vice President; Finance Anthony Gibney - Chief Financial and Business Officer Teresa Bitetti - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 05153U107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 103.39 Most Recent Split Date: (:1) Beta: 0.37 Market Capitalization: $785.74 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.41 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.73 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.33 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 9.09% vs. Previous Quarter: -35.14% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -78.12 12/31/25 - -71.25 09/30/25 - -69.67 ROA 03/31/26 - -64.08 12/31/25 - -59.06 09/30/25 - -58.15 Current Ratio 03/31/26 - 7.09 12/31/25 - 8.15 09/30/25 - 9.04 Quick Ratio 03/31/26 - 7.09 12/31/25 - 8.15 09/30/25 - 9.04 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 1.04 12/31/25 - 2.16 09/30/25 - 2.49 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©